Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentre, double-blind, placebo-controlled, dose-ranging study of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis
2006-001161-42Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daclizumab in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoint: Annualized relapse rate at 52 weeks. Started May 2006; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-001161-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001161-42.